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Tryptophan involves in a range of biological processes including protein 
and biogenic nitrogen-compounds synthesis. It is metabolized to kynurenine 
by indoleamine 2,3-dioxygenase1 (IDO1) that is the first rate limiting 
enzyme. IDO1 expresses ubiquitously in the body with heightened 
expressions in intestinal tissues. To examine the function of IDO1 in colon, 
transcriptome analysis using microarray was performed in both Ido1 knock-
out (Ido1-/-) mice and wild type (Ido1+/+) mice. Differentially expressed 




their biological functions. Gene set enrichment analysis showed that 
inflammatory response was the most significant category which was 
modulated by IDO1 gene. This observation prompted us to study the 
function of IDO1 in inflammatory bowel disease mouse model. In DSS-
induced ulcerative colitis model, the disease was more severely developed 
in Ido1+/+ mice compared with Ido1-/- mice. Total RNAs of inflamed colon 
tissues from both Ido1+/+ and Ido1-/- mice were applied to microarray in 
order to find the significant signaling pathways affected by Ido1 deficiency. 
TLR signaling and NF-kB signaling were turned out to be responsible for 
generating the difference in disease progression between those two 
genotypes. Dramatic changes in TLR signaling and NF-kB signaling 
resulted in substantial changes in expressions of many pro- and anti- 
inflammatory cytokines and chemokines. These findings suggest that IDO1 
play roles in producing inflammatory responses and modulating 
transcriptional networks during colitis development.  
 
Key words: tryptophan, IDO1 (Indoleamine 2,3-dioxygenase1), colitis, 
transcriptome, inflammatory response 
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The metabolism of amino acids has been the subject of numerous 
interesting studies over the last years. Among the 20 amino acids that 
constitute proteins, tryptophan is especially noteworthy, because for many 
organisms (including humans), tryptophan is an indispensable amino acid 
that should only be up-taken through diet. Tryptophan is the precursor of 
multifarious aspects of nutrition and metabolism. Tryptophan is involved 
with a variety of processes including protein synthesis and is an important 
biochemical precursor producing biogenic nitrogen-containing compounds 
such as serotonin (a neurotransmitter), melatonin (a neurohormone), 
tryptamine, and tryptophan metabolites similar to kynurenines.  
In mammals, tryptophan is catabolized along in variety routes. Tryptophan 
primarily contributes in two pathways: the synthesis of nicotinamide 
adenine dinucleotide (NAD+), a coenzyme importantly required to energy 
metabolism via the kynurenine pathways, and synthesis of the putative 
transmitter serotonin, an important neuromediator regulating gastrointestinal 
functions, mood, appetite, and sleep via the serotonin signaling pathway. 
Approximately 95% of serotonin content in the body is found in the 
intestine (Levin et al., 2013). The conversion of tryptophan to serotonin 




further converted into melatonin. Majority of tryptophan is known to be 
metabolized by kynurenine pathway in which tryptophan degrades through a 
series of metabolic reactions (Rios-Avila et al., 2013). Both key enzymes, 
indoleamine 2,3-dioxygenase1 (IDO1, also known as tryptophan pyrrolase) 
and tryptophan 2,3-dioxygenase (TDO, also known as tryptophan 
oxygenase), catalyze the oxidative cleavage of L-tryptophan (L-Try) to N-
formyl-L-kynurenine in the first and rate-limiting step of the kynurenine 
pathway, depending on tissue and cell types (Stavrum et al., 2013). In 1937, 
TDO was first found to be present in the liver, catalyzing the first step of the 
kynurenine pathway (Miller et al., 2004). In fact, TDO operates mainly in 
the liver (Le Floch et al., 2011) and its expression is induced by tryptophan 
itself or by cortisol, which is secreted in response to stress. On the other 
hand, in the same year, an enzyme was detected in the extra-hepatic tissues 
that catalyze the same oxidative rings’ cleavage of tryptophan named IDO1 
in the rabbit intestine (Takikawa et al., 2005). It has been reported that IDO1 
was ubiquitously distributed in extra-hepatic tissues such as the colon 
(primarily distal colon) (Matteoli et al., 2010), small intestine (primarily 
terminal ileum) (Mellor et al., 2004), brain (Kwidzinski et al., 2005), spleen 
(Boasso et al., 2007), lung (Romani et al., 2008), and in cells including 
macrophages, dendritic cells (DCs) (Mellor et al., 2004). IDO2, a paralogue 




IDO2 functions like IDO1 in tryptophan metabolism, but is expressed in 
kidney, liver (Fatokun et al., 2013), and reproductive system (Fukunaga et 
al., 2012), showing a different tissue distribution to that of IDO1 (Murakami 
et al., 2013) as well as very low activity.  
In the last decade, the IDO1-initiated tryptophan metabolism has been 
attracting more interest because of its great potential effect on various 
physiological functions. The first discovery of the role of IDO1 expressed in 
the placenta, whereby maternal T cell mediated immunity during gestation, 
indicated that IDO1 can regulate T cell activity through tryptophan 
catabolism (Munn et al., 1998). They administered 1-methyl-tryptophan (1-
mT), which inhibits IDO1 activity, to pregnant mice and found IDO1 
suppressed T cell proliferation. In addition, several studies have shown one 
of the biological functions of IDO1 is to act as an immune-suppressor 
mediated primarily by T cells in the adaptive immune system. Terness et al. 
(2002) showed that up-regulated IDO1 increased production of tryptophan 
metabolites, which generated cell-cycle arrest of T cell, further promoted 
apoptosis of T cell and induced regulatory T cell differentiation. More 
recently, a new immune escape model has been proposed for tumors based 
on the interactions of the IDO1 function and T cell response. High IDO1 
expression by tumor cells can contribute to recruitment of antigen-




escape (Balachandran et al., 2011). Likewise, treatment with an IDO1 
inhibitor has also been reported to reduce the volume of tumors, suggesting 
that the competitive inhibitor of IDO1 may be a novel molecule for tumor 
immunotherapy. Despite the given the immune-modulatory role of IDO1, 
the mechanism by which IDO1 mediates immune tolerance is a field of 





Aim of this study 
In this study, we performed for the first time a whole genome 
transcriptional profile analysis to investigate the role of IDO1 on tryptophan 
metabolism by using Ido1 knock-out mice, leading to the identification of 
new molecules and describing functionally distinct molecular mechanisms 
regulated by IDO1 expression. This first large-scale profiling may enhance 
understanding of the IDO1 biological activity, and identify novel potential 
target genes to be exploited as candidates related to tryptophan metabolism. 
Moreover, we aimed to elucidate pathophysiological mechanisms by which 
IDO1 play roles in colitis development through looking at transcriptional 











Ⅱ. Materials and Methods 
 
Animals 
Ido1-/- mice of the C57BL/6J background were obtained from The Jackson 
Laboratory (Bar Harbor, Maine, USA). Ido1-/- mice were crossed with 
C57BL/6J (The Jackson Laboratory) to generate the Ido1-/- and Ido1+/+ 
offspring used in this study. Genotypes of knockout mice were verified via 
PCR typing. The mice used were 6–12 weeks old and weighted 18–23g. 
Age-matched female mice were used in experiments. Animals were 
individually housed in plastic cages under specific pathogen-free conditions 
at the Center for Animal Resource Development of Seoul National 
University College of Medicine (Seoul, Korea). The room was controlled 
with constant temperature (25 ± 2ºC), humidity (55 ± 10%), and a 12-hour 
dark/light cycle. All animal experiments were carried out in accordance with 







Induction of Colitis 
To generate an acute colitis experimental model, DSS (molecular mass 
36,000-50,000Da; MP Bio-chemicals, LLC, Illkirch, France) was added to 
drinking water at concentrations of 1% (n=5) or 2% (n=4) (w/v), which was 
given ad libitum for 7 days. Control mice received drinking water without 
DSS (n=3). The subsequent course of colitis development was evaluated by 
monitoring the daily weight changes. Colitis severity also was scored by 
evaluating the clinical disease activity through daily observing of the 
following parameters: weight loss (0 points = No weight loss, 1 points = 5–
10% weight loss, 2 points = 11–15% weight loss, 3 points = 16–20% weight 
loss, 4 points = >21% weight loss); stool consistency (0 points = normal and 
well formed, 2 points = very soft and unformed, 4 points = watery stool); 
and bleeding stool score (0 points = normal color stool, 2 points = reddish 
color stool, 4 points = bloody stool). The disease activity index (DAI) was 
calculated by the combined scores of weight loss, stool consistency, and 
bleeding, as detailed in Table 1. All parameters were scored from day 0 to 





Table 1. Disease Activity Index (DAI) Criteriaa 
Weight loss Stool consistency Fecal bleeding 
 
0 = No weight loss 
 
1 = 5-10% weight loss 
 
2 = 11-15% weight loss 
 
3 = 16-20% weight loss 
 
4 > 21% weight loss 
 
 
0 = Normal 
and well formed 
 
 
2 = Very soft 
    and unformed  
 
 
4 = Watery stool 
 








4 = Bloody stool 
 
a. Cooper H, Murthy SNS, Shah RS, Sedergran DJ: Clinicopathologic study of dextran 
sulfate sodium experimental murine colitis. Laboratory Investigation; a Journal of 








At the 8th day after DSS-colitis induction, mice were sacrificed and entire 
colon was quickly removed, cut open lengthwise, and gently flushed with 
sterile phosphate-buffered saline (PBS) to remove any traces of feces. Colon 
segments were immediately frozen in liquid nitrogen and stored at -80 °C for 
subsequent total RNA extraction. For histological analysis, colon segments 
were fixed in 10% buffered formalin phosphate and stored at room 





Histological Analysis of Colitis 
 
Routinely processed, paraffin-embedded sections of the colon samples 
were prepared and stained with hematoxylin and eosin (H&E) for 
histological grading. Histological scores, including severity of colitis, were 
evaluated in a blinded manner as previously described by Laroui et al. 
(2012). Grades were evaluated from 0 – 4 for the following three criteria: 
severity inflammation (0, rare inflammatory cell in the lamina propria; 1, 
increased inflammatory cell in the lamina propria; 2, confluence 
inflammatory cell extending into the submucosa; and 3, transmural 
extension of the inflammatory infiltrate), damage (0, none; 1, loss of the 
basal 1/3 of the crypt; 2, loss of the basal 2/3 of the crypt; 3, loss of the 
entire crypt but intact epithelial cell; and 4, loss of the entire crypt and of the 
surface epithelial cell), extension (0, none; 1, focal; 2, lesion involving 1/3 
of the intestine; 3, lesion involving 2/3 of the intestine; and 4, lesion 
involving the entire intestine). Scores for each criterion were added to give 
an overall inflammation score for each sample of 0-11. The histological 
grades were determined for each section, and the sum of the grades was 
reported as the inflammation score for each mouse. Two histopathologists 






Microarray Hybridization and Scanning 
 
For microarray hybridization, total RNA was isolated by homogenizing the 
samples from the colon tissue and purified using a DNA-free RNA isolation 
kit (RNAqueous-4PCR kit; Ambion, Austin, TX, USA) in accordance with 
the manufacturer’s instructions. Total RNA integrity and quantity were 
assessed with a NanoDrop 2000 Spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE) before the microarray experiments. Only total 
RNA with an OD 260/280 ratio > 2.0 was used for microarray hybridization. 
RNA samples were first amplified for array analyses using the Illumina 
TotalPrep RNA Amplification Kit (Ambion, Austin, TX, USA) according to 
the manufacturer’s instructions. Briefly, 500ng of total RNA was used to 
prepare labelled cRNA with overnight incubation according to the 
manufacturer’s protocol. The quality and quantity of the labelled cRNA 
were monitored using a NanoDrop 2000 Spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE). Amplified cRNA (1.5g) was hybridized on 
MouseWG-6 Expression BeadChip arrays, containing more than 45,200 
well-annotated Ref transcripts, according to the manufacturer’s standard 
protocol. The arrays were then scanned on a BeadArray Reader 
(BeadStation 500G Instrument, Illumina Inc.), and Spot images 
identification and quantification were obtained by the Genome Studio 




Identification of Significant Genes 
 
The raw data was log-transformed, and normalized by quantile 
normalization method using Genome Studio software (Illumina Inc.). 
Significant difference between two genotypes in each dose (0% [baseline],  
1% treatment, 2% treatment), differences between dose response effect in 
each genotype, and difference between genotype x dose interaction were 
identified using ANOVA test (p < 0.05) on log2-transformed normalized 
intensities using by Partek® Genomics Suite software v6.3 (Partek, St Louis, 
MI) (http://www.partek.com/partekgs). Transcripts with more than 2-fold 
differential expression and a false discovery rate (FDR) < 0.01 were selected 













Functional Enrichment and Clustering Analysis 
 
Functional categorization analysis was performed based upon gene 
ontology consortium (GO). Gene Set Enrichment Analysis (GSEA) was 
done (http://www.broadinstitute.org/gsea/index.jsp) to examine the 
significance of each functional category classified by GO. Hierarchical 
clustering analysis was carried out with Genesis software v1.7.5 (Sturn et al., 

















Data were expressed as the mean ± SEM. Statistical significance (p value < 
0.05) was evaluated either by unpaired student’s t test between two groups 
or two-way analysis of variance (ANOVA) to compare multiple groups 
using dose and genotype as factors. When appropriate, one-way ANOVA 
followed by the Duncan’s multiple-range test was used for post hoc analysis 
to determine differences between groups. To maintain consistency, unpaired 
student’s t test or two-way ANOVA test was used for all comparisons. 
Statistical analyses were performed using Graph Pad Prism 5 software 
(GraphPad Software Inc., La Jolla, CA, USA) and SAS Enterprise Guide 
6.1 (SAS Institute Inc., Cary, NC, USA). For gene analyses, significances 
for functional enrichment of specific genes were determined by a right-
tailed Fisher’s exact test as the negative log of the probability that the 





   Ⅲ. Results 
 
1. Identification of Differentially Expressed Genes in Ido1-/- 
Mice 
As the first attempt to identify targets of IDO1, which catalyzes the first 
and rate-limiting step of tryptophan degradation, microarray analysis was 
performed using by Ido1-/- and Ido1+/+ mice. Principal-component analyses 
(PCA) confirmed that Ido1-/- mice were readily distinguished from Ido1+/+ 
mice, as shown in Figure 1. To define those genes whose expression 
distinguishes Ido1-/- from Ido1+/+, differential gene-expression analysis was 
performed using a stringent cutoff (> 2-fold change, 1% false discovery rate 





Figure 1. PCA (Principal-component analysis) Plot of Ido1-/- vs. Ido1+/+ Mice 
3-D view of PCA scores plot of Ido1-/- group (n=3) versus Ido1+/+ group (n=3). 
Groups are shown by different colors and dots represent individual strains. Blue 
spots represent Ido1+/+ group and the red spots represent Ido1-/- group. On a 3D-
PCA plot of Ido1-/- group can be clearly distinguished from Ido1+/+ group. Blue 












































Figure 2. Heat Map of Differentially Expressed Genes in Comparison of Ido1-/- 
and Ido1+/+ Mice 
Hierarchical clustering and heat map of up- or down- regulated genes that are 
differentially expressed (> 2-fold, 1% [FDR]) by IDO1. The 3 samples on the left 
are Ido1+/+ group controls and the 3 samples on the right are Ido1-/- group indicated 
on each one individaully. The genes differentially expressed are listed from top to 
bottom along the right edge of the heat map. Red indicates high relative expression 




Among the genes regulated by IDO1, we focused initially on those gene 
expressions associated with tryptophan metabolism. As expected, we 
confirmed that differentially expressed genes involved in a series of gene 
encoding enzymes downstream of IDO1, which were referred to as the 
kynurenine pathway of tryptophan degradation through a series of metabolic 
reactions and serotonin signaling pathway of the conversion of tryptophan 
to serotonin (Figure 3A). Only five of the genes, Ido1, Ido2, Kmo, Haao, 
and Alb1, showed significantly (2-fold greater) differential expression on the 
two groups (Figure 3B). Interestingly, IDO1 deficiency not only reduced 
the expression of genes associated in NAD+ biosynthesis pathway 
(kynurenine pathway) but also increased the expression of genes related to 
serotonin signaling pathway, including Tph1, Ddc, and Slc6a4 via negative 


























Figure 3. The mRNA Levels of Genes Related to Tryptophan Metabolism 
(A) The major metabolic pathway of tryptophan. (B and C) Differential expression 
of a selection of genes from (A) in the colon tissue was determined by 
quantification of fold mRNA in unchallenged Ido1-/- and Ido1+/+ littermates where 
the values for Ido1+/+ mice were set 1.0. Bar with * indicate significant difference 
at P < 0.05 by unpaired student’s t test or > 2-fold at least on one comparison. (B) 
Expression of genes related kynurenine pathway. (C) Expression of genes related 
serotonin signaling pathway. 




To establish which pathways were the most selectively dysregulated in 
Ido1-/- mice, we applied a set of functional databases (ingenuity pathway 
analysis (IPA)) to the list of differentially expressed genes. Our analysis 
revealed a strong enrichment for genes associated with inflammatory 
response, suggesting that IDO1 is a key molecule mediating inflammatory 
response (Figure 4). Similarly, gene set enrichment analysis (GSEA) also 
highlighted that genes associated with inflammatory response are 
differentially expressed between Ido1-/- and Ido1+/+ (FDR < 0.01) (Figure 5). 
In addition, several genes, including H2-dmb1 and H2-dmb2, were found to 
be down-regulated (more than two-fold significantly differentially 
expressed), and relative gene expression of Hoxd10 (Homeobox D10), 
which is a transcription factor that induces cell differentiation such as 
epithelial cell, was higher in Ido1-/- mice compared to controls. These data 
suggest that IDO1-deficiency helps re-establishing healthy colon epithelia 
and has a protective effect of inflammation without inflammatory stimuli. 
Such findings compelled us to examine how IDO1 contributes to colonic 



































































































































































































































Figure 5. GSEA (Gene Set Enrichment Analysis) of Data Sets 
We performed gene-set-enrichment analysis (GSEA) to determine whether the 
filtered gene list from Ido1-/- mice vs. Ido1+/+ mice showed specific enrichment in 
the inflammatory response in the rank-based analysis. Rank of 102 genes in our 
data sets ordered by expression level with enrichment plots for the up-regulated 
and down-regulated genes. ES (Enrichment Score) is a value that represents how 
well the gene set is enriched within the selected gene list. The FDR q value < 0.01 
for specific enrichment of the gene set is as indicated. The leading edge analysis of 












2. IDO1 Leads to Increased Susceptibility to Experimental 
DSS-induced Colitis 
Based on the finding that IDO1 affects inflammatory response, we sought 
to define the contribution of IDO1 to colitic disease. We used an established 
murine model of colitis induced by oral administration of DSS, a reagent for 
mucosal epithelial cells that disrupts barrier function (Strober et al., 2002). 
Responses of Ido1 knock-out mice were compared to those of their 
littermate wild-type controls. A DSS concentration of 2% (w/v) in the 
drinking water for 7 days is known to induce strong colitis, but we need to 
identify difference of both genotypes in mild colitis. For this reason, Ido1-/- 
and Ido1+/+ mice were given either 1% (w/v) or 2% (w/v) DSS in drinking 
water. Clinical endpoints of disease were evaluated 8 days after initiating the 
DSS treatment. Changes in body weight during the disease progression are 
shown in Figure 6. Weight loss is a reliable method to assess DSS colitis 
severity; as shown in Figure 6, following induction of colitis, Ido1+/+ mice 
exposed to 2% DSS concentration lost weight much more severely than did 
Ido1-/- mice exposed to 2% DSS concentration (p < 0.05, unpaired student’s 
t test). By comparison, at 1% DSS concentration, no significant differences 
were observed in body weight loss between Ido1-/- and littermate controls 
(p=not significant). Notably, Ido1-/- mice showed reduced susceptibility to 





Figure 6. Changes in Body Weight 
Body weight curves of Ido1-/- and Ido1+/+ mice in an acute model of DSS-induced 
colitis (weighed daily) for 7 days. Data are presented as the mean of each genotype. 
(n = 3-5 per group). P value were calculated with unpaired student’s t test, * p < 








































































































































































































































































































































































Additional endpoints including disease activity index (DAI) over the 
course of colitis (Figure 7, p < 0.05 by unpaired student’s t test) and colon 
contraction (Figure 8, A and B) also revealed increased disease severity in 
Ido1+/+ mice comparing to Ido1-/- mice (p < 0.05 by unpaired student’s t test), 
suggesting that IDO1 produces significant improvements in clinical 
outcomes of colitis in DSS treated mice. 
Histological examination showed that Ido1+/+ mice had increased 
susceptibility to DSS treatment (Figure 9). However, there were no obvious 
differences in histological analysis between Ido1+/+ and Ido1-/- in 2% DSS 
treatment group, since tissue damages were too much severe in both 
genotypes. The increased damage in DSS-induced Ido1+/+ mice correlated 
with enhanced expression of genes encoding inflammatory markers, 
including monocyte chemotactic protein-1 (MCP-1), matrix 
metalloproteinase3 (MMP3), and a transporter associated with antigen 
processing1 (TAP1) primarily in the colon (Figure 10). Such findings 



























Figure 9. H&E Staining of Colon Tissue Sections 
The figure is the representative H&E staining of colon tissue sections (n=3-5 per 
group, magnification 100X for upper pannels and 200X for lower pannels). Severe 
mucosal mononuclear cell infiltration and disruption of the normal crypt 









































Figure 10. The mRNA Levels of Genes Involved in Inflammation   
The increased damage in DSS-induced Ido1+/+ mice correlated with enhanced 
expression of genes encoding inflammatory markers primarily in the colon. Data 
are expressed as means ± SEM (n= 3-5 for each group). Bar with different 
superscripts within the same gene are significantly different at P < 0.05. Two-way 
ANOVA was used to compare with main effect (genotype and dose) and an 
interaction.
Mcp-1 Mmp3 Tap1
Genotype 0.4249 0.3760 0.0130
Dose <0.0001 <0.0001 0.0002





3. IDO1 Regulates the Expression of Multiple Inflammatory 
Genes in DSS-induced Colitis 
To gain insights into the molecular mechanism of the inflammatory 
bioactivity of IDO1 in this murine model of colitis, transcriptome of DSS-
treated Ido1-/- mice was analyzed using microarray, and littermate Ido1+/+ 
mice were used as controls. The RNA samples were reverse transcribed, 
then hybridized to a Bead Chip Array MouseWG-6 v.2 slide containing 
about 45,200 oligonucleotides. Data from the microarray were further 
analyzed using the Genome Studio software. We determined differential 
gene regulation as a significant result if there were a 2-fold change in 
expression in biological replicates in comparison with controls. By the 1% 
false discovery rate in ANOVA test, we identified 5684 genes differentially 
expressed in the comparison of the six different groups.     
First of all, we confirmed the transcript level of IDO1 was significantly 
increased in inflamed colon tissues, suggesting that IDO1 is associated with 
inflammatory responses. Additionally, we observed a number of 
differentially regulated targets caused by IDO1 deficiency in DSS-induced 
colitis. PCA were used to visualize the overall gene expression patterns 
from Ido1+/+ mice and Ido1-/- mice. We found that Ido1-/- mice had a distinct 




whereas no evident difference was observed between 1% DSS treatment 















Figure 11. PCA Plot of Transcriptome Analysis 
3-D view of PCA scores plot of data obtained on Ido1-/- mice versus Ido1+/+ mice  
treated with DSS. On a 3D-PCA plot of 2% DSS treated Ido1-/- group can be 
significantly seperated from 2% DSS treated Ido1+/+ group. Each spots represents 
individual mouse in the group. Blue spots, Ido1+/+ group ; Red spots, Ido1-/- group; 
Purple spots, Ido1+/+ + 1% DSS treatment group, Green spots, Ido1-/- + 1% DSS 
treatment group; Sky blue spots, Ido1+/+ + 2% DSS treatment group; Orange spots. 











PCA explains overall changes in gene expression profiles, but provide 
few insights into the biological meaning. To determine the functional 
relevance of significant genes affected by IDO1 in their gene expressions, 
we categorized those genes based on their biological functions and tested 
their significance using IPA. Pathway analysis revealed a large number of 
regulated genes involved in inflammatory response, cancer, organismal 
injury, and abnormalities as the key functions that affected IDO1 in Ido1-/- 
mice (Figure 12). We then focused on inflammatory response pathway that 
was the most significant category modulated by IDO1 deficiency. There 
were 864 genes in total belonged to inflammatory response category. 
Specifically, we confirmed inflammation-related networks such as IFN-r, 
IL-1b, IL-6, toll-like receptors (TLRs) and NF-kB. Our the most striking 
result was that majorities of members in TLR signaling were down-
regulated in their expressions in Ido1-/- mice, suggesting that TLR signaling 























































































































































































































































































4. Absence of IDO1 Resulted in Suppression of TLR 
Signaling 
Members in TLR signaling were dramatically down-regulated in their gene 
expressions by IDO1 deficiency. Transcript levels of TLR – Tlr2, Tlr4, Tlr5, 
Tlr6, Tlr7 and Tlr13 were significantly reduced (p<0.05, one-way ANOVA) 
in Ido1-/- mice compared to Ido1+/+ mice in DSS-induced colitis models 
(Figure 13, A and B). TLRs belong to the family of pathogen-associated 
pattern recognition receptors and trigger intestinal inflammation when the 
epithelial barrier is breached by pathogenic microbes. After binding of 
ligands to TLR triggers a cascade of signaling events via the TLR-complex, 
downstream molecules are activated and translocated into the nucleus, 
where they activate transcription factor like c-Fos and c-Jun. We observed c-
Jun expression was significantly decreased in Ido1-/- mice compared to 
























Figure13A. Differential Expression of a Selection of Genes Associated with 
TLR signaling                                                          
Differential expression of a selection of genes associated with TLR signaling (Tlr 
2,4,5,6,7,13) in Ido1-/- versus Ido1+/+ mice. Data are presented as means ± SEM (n 
= 3-5 for each group). Bar with different superscripts within the same gene are 
significantly different at P < 0.05. Two-way ANOVA was used to compare with 
main effect (genotype and dose) and an interaction.  
Tlr2 Tlr4 Tlr5 Tlr6 Tlr7 Tlr13
Genotype 0.0006 0.3553 0.8772 0.0026 0.7282 0.0388
Dose <0.0001 <0.0001 0.0013 <0.0001 0.0044 <0.0001
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Figure13B. Pathway Model of TLR Signaling Based IPA Knowledge               
Pathway model of TLR signaling based IPA knowledge. Genes in blue color 
indicate down-regulation and in red color indicate up-regulation.  
  




In this study, we also ascertained that TLR triggered cascades downstream 
signaling molecules like MyD88 (myeloid differentiation primary response 
gene 88), p38 MAPK (p38 map kinase), JNKs (JUN N-terminal kinases), 
IRF5 (interferon regulatory factor 5), and NF-kB (nuclear factor kB) are 
down-regulated (Figure 14, A and B). All TLRs except TLR3 signal through 
MyD88-dependent pathway. TLR3 signals only through MyD88-
independent TRIF-dependent pathways, while TLR4 is distinct as it can 
signal through both MyD88-dependent as well as MyD88-independent 
pathways (Shikha Tarang, 2012). MyD88, a key adaptor protein in the signal 
transduction cascades, which shared most of the TLRs, in this study, 
MyD88-dependent TLR signaling pathways have been identified (Figure 
13B), suggesting that the differences in colitis development status between 
Ido1-/- and Ido1+/+ mice described in previous sections are resulted from 
dysregulation of TLR-MyD88 signaling pathway. For the further 
understanding of the molecular mechanisms regulating the expression of 
TLRs, we investigated the mechanism by which IDO1-deficiency down-






MyD88 Jun Irf5 Nfkb1
Genotype 0.0341 0.7390 0.1560 0.0176
Dose <0.0001 0.0011 0.0002 0.0001
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Figure14B. Pathway Model of NF-kB Signaling Based IPA Knowledge              
Pathway model of NF-kB signaling based IPA knowledge. Genes in blue color 








5. MUC1 Suppresses TLR Signaling  
A number of studies reported intestinal tissues in colitis had impaired and 
permeable mucosal barriers. Mucin is the first line of host defenses against 
invading bacteria, and its alteration severely affects epithelial barrier 
function. Increased bacterial invasion and translocation primarily depend 
upon depletion of the thick mucin layer or mucin wash out due to mucosal 
inflammation. Therefore, to determine whether the enhanced inflammatory 
response in colon tissue of Ido1+/+ mice was due to impaired host defense in 
these mice, we assessed the gene expression of Muc1 that has been up-
regulated for defense activity in colitis. A basal low-level expression of 
Muc1, which was a similar level in Ido1-/- and Ido1+/+ mice, significantly 
increased in Ido1-/- mice during inflammatory stimuli compared to Ido1+/+ 
controls (Figure 15).  
This data suggests that IDO1 markedly affected mucin release to restrict 
the mucosal damaging effects of DSS, such as mucus depletion and crypt 
inflammation. There are several studies on the regulation of TLRs by Muc1 
where TLRs were suppressed by Muc1 in vivo and in vitro (Ueno et al., 
2008; Williams et al., 2009). The evaluated levels of Muc1 under 
inflammatory conditions lessen inflammation by inhibiting further 




results suggest that expression of Muc1 may be therapeutically important 




















Figure15. Colonic mRNA Expression Level of Muc1 Genes after DSS 
Treatment  
Data are presented as means ± SEM of each genotype (n= 3-5 per group). Bars 
with different superscripts within the same gene are significantly different at P < 
0.05. Two-way ANOVA was used to compare with main effect (genotype and dose) 















6. Inflammatory Cytokines and Chemokines Production in 
Colon is Affected by IDO1 
The inflammatory role of IDO1 was dependent on the TLR-MyD88 
signaling pathway as above results. TLR-triggered molecules further lead to 
the production of pro-inflammatory cytokines (Figure 13B) and chemokines, 
which activate adaptive immunity and mount an effective immune response 
against invading pathogens (Miggin et al., 2006). Binding of ligands to 
TLRs initiate a complex signaling cascade leading to the activation of 
several pro-inflammatory cytokines, which via autocrine and paracrine 
effects, initiates a cascade of intracellular signaling. In addition, MyD88 
deficiency abrogates or delays pro-inflammatory responses to various TLR 
ligands including LPS, peptideglycan, flagellin, and CpG (Takeda et al., 
2003). Therefore, we investigated the in vivo effects of IDO1 on 
inflammatory responses and production of local inflammatory cytokines 
mechanistically linked to inflammatory-related colonic injuries in DSS-
induced colitis.  
The gene expression profiles of cytokine and chemokine in colon tissues 
of DSS-treated Ido1-/- mice and their littermate controls were analyzed 






































Figure16. Expression Profiling of Inflammatory Cytokines and Chemokines in 
Colon Tissue after DSS Treatment  
Heat map of cytokines and chemokines genes that are differentially expressed in 
Ido1-/- versus Ido1+/+. One-way ANOVA was used to determine the significant 
difference among the groups. The given values are the average of normalized 




mRNA expressions of pro-inflammatory cytokines including Il1b, and Tnf, 
central mediators of inflammation, were elevated in colonic tissue of Ido1+/+ 
versus Ido1-/- mice (Figure 17A). The expressions of the anti-inflammatory 
cytokines including Il7 and Il18 mRNAs were decreased in Ido1+/+ mice 
(Figure 17B). These results implied that TLRs signaling was inhibited by 
IDO1-deficiency, which suppressed pro-inflammatory cytokines and 
chemokines production through the regulation of a multitude of 





























Figure17. The mRNA Levels of the Genes Related to Pro-inflammatory (A) or 
Anti-inflammatory (B) Cytokines in Colon Tissue  
Data are presented as means ± SEM, n=3-5 for each group. Bar with different 
superscripts within the same gene are significantly different at P < 0.05. Two-way 

















7. Inflammation and Tryptophan Metabolism 
We hypothesized that Ido1-/- mice were relatively inefficient at initiating 
tryptophan metabolism, resulting in impaired IDO1 activity, which might 
reduce the production of tryptophan metabolites like kynurenine and 
increase free tryptophan. The inactivated kynurenine pathway may further 
activate the serotonin pathway, increasing serotonin synthesis from its 
precursor-free tryptophan.  
Serotonin is synthesized in neurons of the central nervous system; however, 
interestingly, the vast majority of serotonin was localized in the intestine 
(Levin et al., 2013). As serotonin is bio-synthesized in the intestine, it has 
been reported to play a role in the pathophysiology of IBD and colitis 
(Levin et al., 2013; De Abajo et al., 1999). A previous study reported that 
deviant intestinal serotonin signaling pathway that occurs in the 
pharmacological inhibition or genetic loss of SERT, the major regulator of 
serotonin levels in tissue, leads to abnormal gastrointestinal motility by an 
alternating pattern of diarrhea and constipation, and aggravates 
inflammation of the colon (Manocha et al., 2012). In the TNBS-induced 
colitis mouse model, lack of SERT to investigate the role of serotonin 
signaling in intestinal inflammation enhances the severity of the colitis, 
suggesting that the evaluated endogenous serotonin promotes lymphocyte 




cytokines in the colon (Linden et al., 2003).  
In the present study, we confirmed the role of serotonin generated by IDO1 
deficiency in regulating intestinal inflammation in Ido1-/- mice treated by 
DSS. The differences in the colitis in Ido1-/-mice and Ido1+/+ mice is due to 
the low serotonin content of the colon by normal SERT activity which is 
required to removal of serotonin from its extracellular receptor. Transcripts 
encoding SERT were quantified in the colon from each group of mice. 
Inflammation possibly increased the tryptophan uptake, and led to down-
regulation of SERT with a coincident increase in the availability of 
serotonin release. Our result showed that the abundance of transcripts 
encoding SERT is up-regulated over that in Ido1-/- compared to controls 
(Figure 18). An increase in SERT expression would reduce the pro-
inflammatory effects of serotonin, and decrease the severity of inflammation. 
It is possible to inhibit intestinal mucosal serotonin signaling selectively and 





To find out the correlation with Ido1 deficiency and the conversion of 
tryptophan to serotonin, mRNA expression of Tph1, the key enzyme for 
serotonin biosynthesis, was examined. The mRNA expression of Tph1 was 
down-regulated in Ido1-/- mice (Figure 18). Previous findings have reported 
an attenuated DSS-induced colitis in TPH-/- mice compared to TPH+/+ mice, 
suggesting a low serotonin level accompanied with down-regulation of IL-
17 and IFN-r levels in colonic tissues (Li et al., 2011). We also investigated 
gene expression which was involved in metabolic pathways of tryptophan in 
IDO1 downstream, as shown in Figure 19A, under inflammatory conditions 
(Figure 19, B and C). Modulation of tryptophan metabolism, especially 
serotonin signaling pathway play a key role, and be a novel target in the 































Figure18. The mRNA Levels of Genes Related to Serotonin Signaling in Colon 
Tissue                                                             
Data are presented as means ± SEM, n=3-5 for each group. Bars with different 
superscripts within the same gene are significantly different at P < 0.05. Two-way 




























Figure19. The mRNA Levels of Genes Related to Tryptophan Metabolism in 
Inflammatory Condition 
(A) The major metabolic pathway of tryptophan in the inflammatory condition (B) 
Differential expression of a selection of genes from (A) in the colon tissue was 
determined by quantification of fold mRNA in DSS-treated Ido1-/- and Ido1+/+ 
littermates where the values for Ido1+/+ mice were set 1.0. Bar with * indicate 
significant difference at P < 0.05 by unpaired student t test or > 2-fold at least one 
comparison. 






Tryptophan metabolism within various organ tissues is linked with 
numerous biological and physiological functions. Tryptophan has critical 
metabolic functions for the regulation of growth, mood, cognition, behavior, 
and immune response (Richard et al., 2009). Dietary tryptophan is primarily 
absorbed via the transport pathway on the luminal surface of small intestinal 
epithelial cells. In particular, gut intestine which has higher IDO1 
expression than other tissues (Matteoli et al., 2010) regulates tryptophan 
homeostasis through degrading excess tryptophan.  
To determine the roles of IDO1 at baseline in the intestine, the gene 
expression profiles were analyzed with an IDO1-deficient mouse model. It 
was found that genes significantly differentially expressed by IDO1 were 
strongly associated with inflammatory response, demonstrating a key role 
for this enzyme mediating inflammatory response in the intestine. This is 
particularly important in the intestine because of the various 
microorganisms and food antigens which challenge the intestinal immune 
system. As the luminal surface of the gastrointestinal tract continually 
interacts with foreign antigen such as pathogenic bacteria, the mucosal 




responses against the antigen attacks. When tolerance has its negative 
tradeoffs, it allows some pathogenic microbes to infect a host immune 
system. Impaired immune tolerance in the intestine can lead to 
inflammatory bowel disease (IBD) like Crohn’s disease (CD) and ulcerative 
colitis (UC) (Zhou et al., 2012; Wolf et al., 2004).  
In the present results, consistent with previous studies, IDO1 expression 
was induced in many intestinal inflammatory conditions of wild-type mice 
(Gurtner et al., 2003), and remarkably exacerbated the inflammation in 
experimental DSS-induced colitis. The underlying mechanism of the roles 
of IDO1 in colitis has been a matter of debate. Opposing result was been 
reported by other researchers using the same model (Takamatsu et al., 2013). 
In the trinitrobenzene sulfonic acid (TNBS) colitis model, the inhibition of 
IDO1 exacerbated colitis due to down-regulating regulatory T cell responses 
within intestinal tract (Takamatsu et al., 2013; Chen et al., 2008). This result 
suggested that IDO1 had therapeutic properties to limit colitis severity. To 
elucidate the role of the enzyme in this colitis model in non-T cell mediated 
mechanism, acute DSS-induced colitis experiment mouse model was 
selected rather than TNBS colitis. 
In this study, we have shown that the IDO1 contributes to DSS-treated 
colitis. Five marked differences between Ido1+/+ mice and Ido1-/- mice with 




IDO1 may cause colonic inflammation early on after DSS treatment. IDO1 
expression and enzymatic activity are related with disease activity. 2) TLRs-
MyD88 signaling dependence: IDO1 may require TLRs-MyD88 signaling 
to cause colitis. 3) Muc1 regulates TLRs signaling: strains with disrupted 
Ido1 may elevate the level of Muc1 mRNA expression which reduce the 
inflammation by inhibiting further activation of TLRs signaling. 4) Pro-
inflammatory cytokines and chemokines production dependence: IDO1 
affects inflammatory cytokines and chemokine production to cause colitis. 5) 
Serotonin signaling pathway dependence: IDO1 regulates serotonin 
signaling to cause colitis.  
These observations supported that the function of IDO1 in intestinal tissues 
regulates the balance between inflammation and regulatory responses in the 
intestine. Especially, there were striking results indicating that disrupted 
TLR signaling was attributable to the attenuation of DSS-induced colitis in 
Ido1-/- mice. In addition, TLR-triggered cascades of downstream mechanism 
molecules like JUN and NF-kB signaling are also directly down-regulated; 
as a result, the release of pro-inflammatory cytokines such as Il-1b and Tnf 
were decreased. This result suggested that IDO1 is a key enzyme which 
mediates by linking the innate and adaptive immune responses.  
Tryptophan degradation via kynurenine pathway by IDO1 has been 




reported to induce by the pro-inflammatory cytokine interferon-r (IFN-r) in 
APCs, and express in inflamed tissue (Takamatsu et al., 2013). For example, 
low level of tryptophan might be detected by the mTOR or stress responsive 
kinase GCN2, both of which respond to low levels of amino acids. GCN2 
has been reported to be necessary for the immunoregulatory effects of IDO1 
in T cells (Munn et al., 2005). These important functions of IDO1became an 
emerging target for cancer, infection, autoimmunity, and other diseases 
characterized by inflammation conditions and immune suppression (Mellor 
et al., 2004; Platten et al., 2012; Klonowski et al., 2012; Blumenthal et al., 
2012). If so, how does IDO1 regulated uptake of tryptophan in the small 
intestine affect DSS-induced inflammation in the intestine? 
In our analysis, both mRNA expression of reduced SERT (which 
terminates serotonin reuptake) and elevated Tph1 (biosynthesizes to 
serotonin) was found to increase the level of serotonin in the intestine. The 
regulation of intestinal inflammation by modulating NF-kB activation and 
the production of pro-inflammatory cytokines from innate immune cells 
were found to be affected by serotonin (Li et al., 2011).   
There is also emerging evidence that serotonin signaling plays an 
important role in inflammation-induced physiological changes, including 
mucin secretion and immunoregulatory effects in the intestine (Keszthelyi et 




al., 2004). Although serotonin has been demonstrated to be involved in 
immune system function, its precise role remains unclear. 
More recently, metabolites of the kynurenine have been considered to play 
a regulatory role in the CNS and the gastrointestinal tract (Stone et al., 
2013). The biologic relevance of IDO1 has been reported in the models of 
inflammation associated with diverse diseases (Zwilling et al., 2011; 
Schwarcz et al., 2012). The metabolic intermediates such as kynurenine and 
quinolinic acid could have a physiological role as agonists or antagonists at 
various receptor sites. They could inhibit proliferation of T cells, and induce 
the apoptosis of activated T cells (Kim et al., 2010). However, relatively 
little information is available regarding the response of tryptophan 
metabolites, and the intricate machinery evolved for the regulatory role of 
tryptophan metabolites in the colon that could still be unknown. Indeed, 
although some tryptophan metabolites have potential palliative properties 
(Pero et al., 2009), some other endogenous tryptophan metabolites are 
known to have toxicity which increases an oxidative stress (Sahm et al., 
2013). These contradictory results revealed the complexity of tryptophan 
metabolism and the various properties of tryptophan metabolites. Therefore, 
further studies are needed to investigate the complexity of tryptophan 





The present report may offer the first comprehensive description of the role 
of the IDO1 at the transcriptome level using a DSS-treated Ido1-/- mouse 
model, and describe new molecular targets which specifically expressed or 
restricted a tryptophan metabolism in relation to colon inflammation 
through a global profiling approach. This may be a novel target of 
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Ido1 knock-out 마우스를 이용한 대장염 
모델에서의 전사체 분석 
 
 
서울대학교 대학원 식품영양학과 
손 우 정 
 
트립토판은 인간을 비롯한 대부분의 동물들에서 합성되지 
않으므로, 반드시 식이를 통해 섭취해야만 하는 필수 아미노산이다. 
트립토판은 다양한 생물학적 과정에서 전구체로서 사용되거나, 첫 
번째 속도 제한 효소인 IDO1(Indoleamine 2,3-dioxyganase)에 
의해 Kynurenine 과 같은 대사 물질로 대사될 수 있다. IDO1 은 뇌, 
비장, 폐 등 인체 내 여러 장기에서 발현되는데, 특히 장 조직에서의 
발현이 가장 높다. 그러나 실제 장 내에서 IDO1 이 하는 역할과 
기능에 관한 연구는 미흡한 실정이다. 따라서 본 연구는 대장 내 
IDO1 의 생체 내 역할 및 기능을 규명하고자 Ido1-/- 마우스와 
Ido1+/+ 마우스에서 IDO1 에 의하여 발현이 조절되는 유전자들을 
microarray 실험을 통해 탐색하였다. Ido1-/-마우스 및 Ido1+/+ 




결과, 총 102 개의 유전자들의 발현이 유의적으로 변화하였다. 
발현이 변한 유전자들에 대한 생물학적 기능을 탐색하고자, Gene 
Set Enrichment Analysis 를 수행한 결과, 염증 반응(Inflammatory 
response)에 관여하는 유전자들이 대부분 유의적으로 변했음을 
확인하였다. 이러한 결과를 바탕으로 염증성 장 질환 모델에서 
IDO1 의 기능 및 역할을 알아보고자 하였다. 10 주령의 암컷 
C57BL/6J wild-type (Ido1+/+) 마우스와 Ido1-/-마우스를 
이용하여 1% 및 2% DSS(Dextran Sulfate Sodium) 음수를 
공급하여 대장염 모델을 유도하였다. 체중, DAI(Disease Activity 
Index, 설사·혈변 점수), 장 길이, 조직학적 손상 정도(H&E 염색), 
염증성 세포 수 등을 확인하였을 때, Ido1-/- 마우스에서 
Ido1+/+마우스에 비해 질병의 진행 정도나 속도가 유의적으로 낮은 
것으로 관찰되었다. 대장염의 발달 및 진행 속도에 기여하는 유의한 
신호전달 경로를 탐색하기 위하여, 염증이 생긴 대장 조직으로부터 
total RNA 를 추출하여 microarray 실험을 수행하였다. 그 결과 두 
유전자형 사이에 질병의 진행 차이를 발생시키는데 기여하는 신호 
전달 경로가 탐색되었다. Ido1-/- 마우스에서 Ido1+/+마우스에 
비해 TLR signaling 및 NF-kB signaling 에 관여하는 대부분의 
유전자들의 발현이 매우 유의적으로 감소했음을 확인할 수 있었다. 
뿐만 아니라 Ido1-/- 마우스에서 많은 염증성 (pro-inflammatory) 
및 항염증성 사이토카인 (anti-inflammatory cytokine) 및 
케모카인들의 발현이 변화됨이 관찰되었다. 위 결과들을 종합하였을 




변화시킴으로써, 대장염 유도 및 진행에 있어 주요 인자로 작용하는 
것으로 제안된다.  
 
주요어: 트립토판, IDO1(Indoleamine 2,3-dioxygenase), 대장염, 전사
체, microarray, 염증 반응  
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